1. Home
  2. NABL vs ADPT Comparison

NABL vs ADPT Comparison

Compare NABL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NABL
  • ADPT
  • Stock Information
  • Founded
  • NABL 2000
  • ADPT 2009
  • Country
  • NABL United States
  • ADPT United States
  • Employees
  • NABL N/A
  • ADPT N/A
  • Industry
  • NABL Computer Software: Prepackaged Software
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NABL Technology
  • ADPT Health Care
  • Exchange
  • NABL Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • NABL 1.5B
  • ADPT 1.8B
  • IPO Year
  • NABL N/A
  • ADPT 2019
  • Fundamental
  • Price
  • NABL $8.25
  • ADPT $13.08
  • Analyst Decision
  • NABL Buy
  • ADPT Strong Buy
  • Analyst Count
  • NABL 4
  • ADPT 8
  • Target Price
  • NABL $9.31
  • ADPT $12.38
  • AVG Volume (30 Days)
  • NABL 749.6K
  • ADPT 1.8M
  • Earning Date
  • NABL 11-06-2025
  • ADPT 11-06-2025
  • Dividend Yield
  • NABL N/A
  • ADPT N/A
  • EPS Growth
  • NABL N/A
  • ADPT N/A
  • EPS
  • NABL 0.01
  • ADPT N/A
  • Revenue
  • NABL $482,397,000.00
  • ADPT $205,216,000.00
  • Revenue This Year
  • NABL $9.79
  • ADPT $32.76
  • Revenue Next Year
  • NABL $8.97
  • ADPT $15.81
  • P/E Ratio
  • NABL $798.73
  • ADPT N/A
  • Revenue Growth
  • NABL 7.40
  • ADPT 21.60
  • 52 Week Low
  • NABL $6.07
  • ADPT $3.98
  • 52 Week High
  • NABL $13.12
  • ADPT $13.68
  • Technical
  • Relative Strength Index (RSI)
  • NABL 55.81
  • ADPT 55.90
  • Support Level
  • NABL $8.10
  • ADPT $12.34
  • Resistance Level
  • NABL $8.45
  • ADPT $13.68
  • Average True Range (ATR)
  • NABL 0.23
  • ADPT 0.59
  • MACD
  • NABL 0.04
  • ADPT -0.06
  • Stochastic Oscillator
  • NABL 60.00
  • ADPT 55.22

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: